Uproleselan sodium is under clinical development by GlycoMimetics and currently in Phase III for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase III drugs for Relapsed Acute Myeloid Leukemia have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Uproleselan sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Uproleselan sodium overview

Uproleselan sodium (GMI-1271) is under the development for the treatment of refractory and relapsed acute myeloid leukemia (AML) in adults and pediatrics, coronavirus disease 2019 (COVID-19) pneumonia, myelodysplastic syndrome, acute myelocytic leukemia, chronic myelogenous leukemia and inflammatory diseases. The drug candidate is administered through intravenous route. It acts by targeting E-selectin. GMI-1271 is a mimetic of naturally occurring carbohydrate (GlycoMimetics).

It was also under development for deep venous thrombosis, pancreatic cancer, multiple myeloma and breast cancer.

GlycoMimetics overview

GlycoMimetics is a clinical-stage biotechnology company that discovers and develops small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s lead pipeline product, uproleselan, is being developed for the treatment of relapsed/refractory acute myeloid leukemia (AML) in adults. GlycoMimetics designs galectin inhibitors for advancing treatment options for various diseases. The company designs and tests viral and bacterial entry inhibitors for dendritic cell receptors. GlycoMimetics uses proprietary glycobiology technology to develop treatments for diseases. It also offers clinical research programs. GlycoMimetics is headquartered in Rockville, Maryland, the US.

For a complete picture of Uproleselan sodium’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.